Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Because of advances in treatment, the 5-year survival rate for people with actue lymphocytic leukemia has increased from 38% in 1974-1976 to 65% in 1995-2001.  
  • “Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease. Strangely…  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • Gains in healthy years of life and social value from cancer R&D
     
  • Since the war on cancer was declared in 1971, our arsenal has tripled. New drugs accounted for around 50-60% of the increase in six-year cancer survival rates since 1975.…